Search Results for: -trf7pw.html

FAQs

FAQs Corporate FAQs Where is Actuate headquartered? Our corporate headquarters is in Fort Worth, Texas How is Actuate stock traded? Our shares are traded on NASDAQ Global Market under the stock symbol ACTU When was Actuate incorporated? Actuate was incorporated on January 16, 2015 When did Actuate go public? Actuate went public on August 13, […]

FAQs Read More »

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib for treatment of patients with pancreatic cancer. Elraglusib (9-ING-41) is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER Read More »

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC). Read More »